Business
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak Ca...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Provides Update on Operations in Response to the COVID-19 Global Outbreak\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, March 20, 2020\n\n\n\nVANCOUVER, March 20, 2020 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today provided an update on the impact of the global outbreak of COVID-19 on its business operations. \n\n \n \n \n \n \n \n\n \nIn early March, the Company began to implement guidelines of its Pandemic Preparedness Plan, including cancelling all corporate travel, exercising social distancing in the workplace and enabling all staff to work from home.  The Company also began to interact on a more frequent basis with the numerous research vendors for all research and development programs to monitor their local situation with regards to the COVID-19 outbreak.\nEric A. Adams, CEO of InMed stated, \"In response to the outbreak of COVID-19, InMed is taking all necessary measures to ensure, first and foremost, the health and safety of our employees while also minimizing the impact to our ongoing operations. We are closely monitoring all program activities with our numerous contract research organizations (\"CROs\") on a daily basis. We are fortunate that our administrative, scientific and clinical teams are able to operate effectively while working remotely. We are committed to doing everything within our power to limit the possible negative effects on our long-term success.\"\nIn regards to InMed's INM-755 program, investigating CBN cream as a topical therapy to treat epidermolysis bullosa, the Company has been in regular communications with the Center for Health and Drug Research in the Netherlands, which is the clinical site conducting the 755-101-HV Phase 1 trial. As this trial is nearing completion, InMed does not anticipate a significant disruption in the remaining treatments and collection of...